Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Tuesday’s analyst upgrades and downgrades Add to ...

Subscribers Only

Inside the Market’s roundup of some of today’s key analyst actions

Pershing Square’s decision to sell its entire investment in Valeant Pharmaceuticals International Inc. (VRX-N, VRX-T) sends an “untimely poor signal,” according to BMO Nesbitt Burns analyst Gary Nachman.

On Monday, Pershing, led by billionaire investor William Ackman, abruptly announced the sale of its entire stake for a loss of more than $3-billion (U.S.). At one time, Mr. Ackman had been one of Valeant’s most vocal defenders.

Report Typo/Error

Follow on Twitter: @daveleeder

 

More Related to this Story

Topics

Next story

loading

Trending

loading

Most popular videos »

More from The Globe and Mail

Most popular